| Literature DB >> 25833390 |
Terzah M Horton1, Richard A Drachtman2, Lu Chen3, Peter D Cole4, Kathleen McCarten5, Stephan Voss6, Robert P Guillerman7, Allen Buxton3, Scott C Howard8, Shirley M Hogan9, Andrea M Sheehan10, Dolores López-Terrada10, Matthew D Mrazek1, Neeraj Agrawal1, Meng-Fen Wu11, Hao Liu11, Pedro A De Alarcon12, Tanya M Trippet13, Cindy L Schwartz14.
Abstract
A Children's Oncology Group clinical trial aimed to determine if bortezomib (B) increased the efficacy of ifosfamide and vinorelbine (IV) in paediatric Hodgkin lymphoma (HL). This study enrolled 26 relapsed HL patients (<30 years) treated with two to four cycles of IVB. The primary endpoint was anatomic complete response (CR) after two cycles. Secondary endpoints included overall response (OR: CR + partial response) at study completion compared to historical controls [72%; 95% confidence interval (CI): 59-83%]. Although few patients achieved the primary objective, OR with IVB improved to 83% (95% CI: 61-95%; p = 0.32). Although not statistically different, results suggest IVB may be a promising combination.Entities:
Keywords: NF-κB; childhood haematological malignancies; clinical trials; paediatric oncology
Mesh：
Substances：
Year: 2015 PMID： 25833390 PMCID： PMC4478135 DOI： 10.1111/bjh.13388
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998